Artelo Biosciences (ARTL) Net Equity Issued and Repurchased (2015 - 2025)

Artelo Biosciences (ARTL) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased rose 2987.72% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $4.6 million (up 4006.25% YoY), while the FY2025 annual figure was $6.2 million, up 5391.96% from the prior year.
• Net Equity Issued and Repurchased held at $1.8 million in Q4 2025 per ARTL's latest filing, from $1.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $18.3 million in Q4 2021 and bottomed at $32000.0 in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $2.7 million across 4 years, with a median of $1.0 million in 2021.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased surged 78.12% — and 2025, when it surged 2987.72%.
• Artelo Biosciences' Net Equity Issued and Repurchased stood at $18.3 million in 2021, then sank by 99.82% to $32000.0 in 2023, then soared by 78.12% to $57000.0 in 2024, then soared by 2987.72% to $1.8 million in 2025.
• Business Quant data shows ARTL's Net Equity Issued and Repurchased at $1.8 million in Q4 2025, $1.8 million in Q3 2025, and $1.1 million in Q2 2025.